1stOncology™: Cancer Intelligence Service – Page 76 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

On September 3, 2026 bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics for the early detection of lung cancer and other lung diseases, reported that President and CEO Maria Zannes will present a corporate update and hold one-on-one investor meetings during the H.C. Wainwright 28th Annual Global Investment Conference being held September 14-16, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Ms. Zannes’ presentation will feature recent and upcoming strategic milestones, commercial adoption and momentum for the Company’s CyPath Lung diagnostic test, and advancements for the proprietary technology platform to develop additional diagnostic and therapeutic applications.

Institutional investors can register here to attend the conference virtually or in-person at the Lotte New York Palace Hotel. Registered investors may request a meeting via the conference website.

A live and archived webcast of the bioAffinity presentation will be available on September 11 at https://bit.ly/BIAFPresentation.

(Press release, BioAffinity Technologies, SEP 3, 2026, View Source [SID1234670585])

Citius Pharmaceuticals to Participate in September 2026 Investor Conferences

On September 3, 2026 Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, reported that Chairman and Chief Executive Officer Leonard Mazur will present and host one-on-one investor meetings at two upcoming investor conferences in New York City.

During his presentations and investor meetings, Mr. Mazur will provide an overview of the Company’s business and recent developments, including the ongoing commercialization of LYMPHIR (denileukin diftitox-cxdl) by the Company’s majority-owned subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR), and the continued advancement of the Company’s late-stage pipeline.

Moody Capital Solutions Conference:

Conference: Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
Dates: September 9–10, 2026
Location: The Westin New York Grand Central, New York, NY
Presentation Date & Time: Wednesday, September 9, 2026, 3:15 pm – 4:00 pm ET
Webcast: webcast link

H.C. Wainwright Conference:

Conference: H.C. Wainwright 28th Annual Global Investment Conference
Dates: September 14–16, 2026
Location: Lotte New York Palace Hotel, New York, NY
Presentation Date & Time: Tuesday, September 15, 2026, 2:00 pm – 2:30 pm ET
Webcast: webcast link
Please note that the presentation dates and times are subject to change. Participants should refer to the final program agenda for up-to-date information.

Investors interested in scheduling a one-on-one meeting with management should contact their conference representative or the Company’s investor relations team.

(Press release, Citius Pharmaceuticals, SEP 3, 2026, View Source [SID1234670584])

Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US

On September 3, 2026 Invagen Pharmaceuticals Inc, a wholly owned subsidiary of Cipla Limited (BSE: 500087) (NSE: CIPLA) reported that it has entered into a strategic partnership with Qilu Pharmaceutical Co., Ltd. (hereinafter referred to as Qilu), for the exclusive licensing and supply of QL2107, a biosimilar to Keytruda (pembrolizumab), for the United States

As part of the agreement, Qilu will be responsible for development, regulatory registration and supply of the product while Cipla USA Inc. will be responsible for the commercialization of the asset by leveraging its strong commercial presence in the defined territory.

The collaboration reflects both companies’ shared commitment to addressing the growing burden of cancer and improving access to advanced biologic therapies.

Commenting on the partnership, Achin Gupta, Managing Director & Global Chief Executive Officer, Cipla, said, "This partnership reflects Cipla’s confidence in the long-term potential of biosimilars and supports our strategy to build a strong oncology-focused portfolio. By combining Qilu’s development strengths with Cipla’s commercial presence and patient-centric legacy, we aim to expand access to high-quality biologics for patients across our focus markets."

Marc Falkin, Chief Executive Officer, Cipla North America, said, "This collaboration is aligned with our strategy to expand our biosimilar portfolio in the coming fiscal years, and we are excited to add QL2107 with Qilu who have been great partners. With our established commercial capabilities, we are well-positioned to successfully launch QL2107, subject to regulatory approval, and help ensure it reaches patients in need while lowering the cost of treatment."

Hanchang Zhang, General Manager of Qilu Pharmaceutical, said, "We are pleased to establish this partnership with Cipla for QL2107. Qilu boasts a robust and growing biosimilar product pipeline. By combining our R&D and manufacturing strengths with Cipla’s U.S. commercial expertise, we aim to bring a high-quality, affordable pembrolizumab biosimilar to U.S. patients."

(Press release, Cipla, SEP 3, 2026, View Source [SID1234670583])

Immuneering to Participate in Upcoming Investor Conferences

On September 3, 2026 Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, reported that management plans to participate in the following upcoming investor conferences:

Cantor Global Healthcare Conference (September 9-11 in New York City)

Format: Fireside Chat and 1×1 Investor Meetings
Date/Time: Thursday, September 10, 2026, from 2:45-3:15 pm ET

H.C. Wainwright 28th Annual Global Investment Conference (September 14-16 in New York City)

Format: Fireside Chat and 1×1 Investor Meetings
Date/Time: Monday, September 14, 2026, from 5:00-5:30 pm ET

The fireside chats will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.

(Press release, Immuneering, SEP 3, 2026, View Source [SID1234670582])

Arvinas to Participate in Upcoming Investor Conferences

On September 3, 2026 Arvinas, Inc. (Nasdaq: ARVN) ("Arvinas" or the "Company"), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, reported that that management will participate in fireside chats at the following upcoming investor conferences:

Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at 1:30 p.m. ET; webcast available here.

Cantor Global Healthcare Conference on Thursday, September 10, 2026, at 2:10 p.m. ET; webcast available here.

Morgan Stanley Annual Global Healthcare Conference on Wednesday, September 16, 2026, at 9:15 a.m. ET; webcast available here.

All webcasts will also be available in the Events and Presentations section of the Company’s website.

(Press release, Arvinas, SEP 3, 2026, View Source [SID1234670581])